Assessing the Actual Risk of Eating Disorders Associated with GLP-1 Medications - Top-Institutions - MDSpire

Assessing the Actual Risk of Eating Disorders Associated with GLP-1 Medications

  • By

  • Theresa Gaffney

  • April 27, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Psychiatry
    • Clinical Pharmacology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Psychiatry
    • Neuroscience

  • #3

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, CA

    Key Differentiators

    • Endocrinology
    • Psychiatry
    • Clinical Research

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Psychiatry
    • Clinical Pharmacology

Original Source(s)

Assessing the Actual Risk of Eating Disorders Associated with GLP-1 Medications

  • by Theresa Gaffney

  • April 27, 2026

Related Content

Epicardial fat area as an independent predictor of atrial fibrillation occurrence and severity

Comparison of the association and discriminatory ability of CVAI, LAP, CI, and AVI for type 2 diabetes in Chinese adults aged ≥ 50 years: a sex-specific analysis

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.